Fuchs Endothelial Corneal Dystrophy Clinical Trial
Official title:
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04440280 -
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
|
Phase 2 | |
| Recruiting |
NCT05376176 -
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
|
Phase 2 | |
| Recruiting |
NCT05826353 -
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
|
Phase 3 | |
| Recruiting |
NCT04387331 -
The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK
|
||
| Active, not recruiting |
NCT04894110 -
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
|
Phase 1 | |
| Completed |
NCT04520321 -
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT05052554 -
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
|
Phase 1 | |
| Completed |
NCT03974230 -
Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France.
|